REAL WORLD EVIDENCE: The New Standard of Proof? 29 January 2015: NEW JERSEY 09:30 Delegate arrivals Welcome introductions Stuart Cooper Meeting Chair CEO Adelphi Group 11:15 12:45 Navigating the choices A guide to developing effective RWE strategies that are fit for purpose Q&A Neil B. Minkoff, MD Pathways to value Framing the role of RWE in the current healthcare accountability environment Q&A Johann Odermann Chief Medical Officer EmpiraMed Inc Managed Markets Consultant PayerStrat Coffee Driving real world decisions: Ways To Use Real World Data to Optimize Patient Care Q&A Gary K. Rice, RPh, MS, MBA Towards a common goal Integrating RWE pre- and post-launch to meet growing demands of regulators, payers, physicians and patients Q&A Jennifer Cook Vice President of Clinical Services Diplomat Specialty Pharmacy Director Value Insight & Communications Adelphi Values * (formerly AstraZeneca) Lunch Customer value creation Data collection systems to create payer, provider and health system solutions Q&A Florian Turk Panel and Audience Debate Chaired by Neil B. Minkoff, MD Shaping up for the challenge How is our industry evolving to face the new evidence demands? Meeting close 15:30 VP Head Global Market Access & Healthcare Solutions Glaxo SmithKline Speaker Bios Neil B. Minkoff, MD Chief Medical Officer for EmpiraMed, Inc Neil B. Minkoff, MD is Chief Medical Officer for EmpiraMed, Inc, working to develop the PRO Portal for capturing self-reported patient outcomes and clinical information to measure real-world comparative effectiveness. In 2012 he was appointed as a Commissioner of the Massachusetts Group Insurance Commission, which provides oversight of health insurance for the Commonwealth of Massachusetts. Johann Odermann Managed Markets Consultant, PayerStrat As Managed Market Practice Leader, Johann provides payer strategy and marketing consultancy to pharmaceutical and biotech organizations, drawing on his many years of healthcare industry and specifically managed market experience. Jennifer Cook Director, Value Insight & Communication, Adelphi Values (formerly of AstraZeneca) Jennifer informs client decisions through the investigation, demonstration and communication of healthcare value. Immediately prior to joining Adelphi Values she worked as a Global Pricing and Market Access Director for AstraZeneca, developing payer pricing and market access strategies and shaping evidence needed for payer value stories, to gain reimbursement deliverables. Florian Turk Vice President, Head Global Market Access & Healthcare Solutions, GlaxoSmithKline Florian is responsible for Global Market Access, Pricing and Healthcare Solutions. His main current research interest is in behavioral models of patient decision making, health care incentive models, health system and health care delivery reconfiguration analysis as well as in the development and implementation of innovative Go-to-Market and commercialization strategies and enabling organizational designs & principles within the industry. Gary Rice Vice President of Clinical Services at Diplomat Specialty Pharmacy: Gary provides leadership, strategy, and planning for all clinical functions across Diplomat Specialty Pharmacy. He works closely with Operations, IT, Business Development, Sales and Marketing, and Managed Markets for tactical positioning and clinical service support from development through implementation, and over sees clinical initiatives and services. REAL WORLD EVIDENCE: The New Standard of Proof? 29 January 2015: NEW JERSEY The Madison, Morristown, NJ In this meeting designed for Senior Pharmaceutical Executives across disciplines, Adelphi invites you to engage in thought-leading debate “How to demonstrate and communicate the better outcomes that health systems want and will pay for … are payers and pharma aligned on the future role of Real World Evidence?” Why attend?  Hear the views of expert speakers from a payer and pharma perspective  Engage in informed discussion with payers and your peers from leading pharma companies Optimize your Real World Evidence strategy to demonstrate therapeutic value to all stakeholders Realising value: Meet shifting evidence demands from authorities, budget holders, physicians and patients to support decisions on your therapies, at launch and beyond Successful evidence collection: Employ new value models to complement traditional RCT end points (case study examples of successful US and EU models; how to avoid pitfalls) Impact on pharma: Debate how major pharma companies are realigning philosophy and processes to recognize Real World Evidence in product development and commercialization Effective Communication: Reach your key healthcare audiences with Real World Evidence that resonates and is relevant to their decision making Featuring an expert speaker panel